Systemic treatments in malignancy.
Research type
Research Study
Full title
The use of, and outcomes associated with, systemic treatments in patients with cancer in routine care in England. Analyses of outcomes using the SACT dataset.
IRAS ID
262026
Contact name
David Dodwell
Contact email
Sponsor organisation
University of Oxford
Duration of Study in the UK
6 years, 0 months, 0 days
Research summary
To study survival outcomes in well-defined large cohorts of patients receiving CDF [cancer drug fund supported] or other drugs with a clearly defined place in therapy for poor prognosis cancer. To compare survival outcomes with those seen in registration level RCTs and other prospective clinical trials. To use data within SACT (chemotherapy database) but also those linked to multiple other NCRAS datasets to define patient characteristics that may influence survival and other outcomes. To study population-level variability in uptake of cancer drugs according to geography, socio-economic status and provider trust.\n\nTo study and develop indicators of significant toxicity including early [<30 day] mortality & hospital admissions. To help inform clinical information provision and decision making by providing a better understanding of outcomes in routine care.
REC name
North of Scotland Research Ethics Committee 1
REC reference
19/NS/0057
Date of REC Opinion
11 Apr 2019
REC opinion
Favourable Opinion